Inflammatory Bowel Disease Treatment Market
Crohn’s disease, gastrointestinal disease due to trauma, bowel obstruction (BO), microscopic colitis, short bowel syndrome, and ulcerative colitis are a few of the common gastrointestinal diseases. According to an article published in Healthline in 2021, ~40% of people across the world were affected by functional gastrointestinal disorders. The Canadian Digestive Health Foundation states millions of Canadians live with digestive diseases; ~20 million Canadians, i.e., two of every three people, suffer from digestive disorders yearly. Enteral nutrition helps administer vital nutrients, which helps maintain strength, energy, and hydration levels in cancer patients (all stages).
Crohn’s disease is a complex, chronic disorder that primarily affects the digestive system. The National Library of Medicine stated that there were 825 cases of IBD per 100,000 people in 2023, including compared to 410 cases of Crohn’s disease and 414 cases of ulcerative colitis and IBD-u. With a prevalence of 0.82%, 322,600 Canadians were had IBD in 2023. Patients with gastrointestinal disease are at an increased risk of nutritional deterioration due to fasting requirements of diagnostic tests, therapeutic dietary restrictions, and loss of appetite due to anorexia or altered nutritional requirements caused due to the disease itself. Thus, enteral nutrition is prescribed for gastrointestinal disease patients, as the enteral route is preferred to provide the required nutrients. Therefore, the rising prevalence of chron’s disease and ulcerative colitis drives the growth of the Inflammatory Bowel Disease Treatment Market.
The Inflammatory Bowel Disease Treatment Market analysis has been carried out by considering the following segments: drug class, disease indication, and distribution channel. By drug class, the market is classified into biologics, aminosalicyclates, corticosteroids, and others. Based on disease indication, the market is bifurcated into Crohn’s disease and ulcerative colitis. In terms of distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Based on geography, the Inflammatory Bowel Disease Treatment Market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). In 2023, North America held the largest market share, and the US dominates the market in this region, as well as in the world. Market growth in this country is attributed to the increase in the prevalence of inflammatory diseases, the presence of major market players and their numerous strategic initiatives. Regional expansion is also being made easier by the region’s improved payment rules, high treatment rates, and rising prescription of innovative medications. The development of innovative treatments through continuing research as well as encouraging government initiatives are also expected to fuel the region’s expansion. For instance, some major groups such as Crohn’s & Colitis Foundation is dedicated to promoting clinical and translational research aimed at curing colitis and Crohn’s disease. Furthermore, Asia Pacific is expected to increase at the fastest rate. Some of the main reasons driving market expansion in the next years are the growing elderly population, which is associated with a higher chance of acquiring inflammatory disorders, the rising prevalence of inflammatory bowel diseases, and improvements in healthcare policy in the area. Furthermore, major players in the region are expected to increase their investments, and the growing use of biologics and biosimilars will likely fuel market growth in the near future.
Inflammatory Bowel Disease Treatment Market: Competitive Landscape and Key Developments
The Inflammatory Bowel Disease Treatment Market analysis is carried out by identifying and evaluating key players in the market across different regions. AbbVie Inc; Takeda Pharmaceutical Company Limited; Pfizer Inc; Biogen; Novartis AG; Lilly; UCB S.A.; CELLTRION INC.; Merck & Co., Inc.; and Johnson & Johnson Services, Inc. are a few key companies operating in the market. Market players adopt product innovation strategies to meet evolving customer demands, maintaining their brand image in the Inflammatory Bowel Disease Treatment Market.
